Skip to main content
Home
  • fr
  • en
  • Anniversary
  • Profile
    • Leadership team
    • Supervisory board
    • Strategic advisory board
    • Founders
    • History
    • Key figures
    • Key competencies
  • Science
    • Innate Pharma, the innate immunity company
    • Immunity & Immunotherapy
    • Bispecific antibodies
    • Bibliography
  • Pipeline
    • Monalizumab
    • Anti-Siglec-9

    • LUMOXITI
    • Lacutamab / IPH4102
    • IPH61
    • IPH43
    • NKp46 NKCE

    • IPH5401
    • IPH5201
    • IPH5301
  • Partners
  • Investors
  • News
    • Press releases
    • Events
    • Innate in the news
  • Career
    • GREAT PLACE TO WORK
  1. Home
  2. News
  3. Press releases

Press releases

  • Innate Pharma releases its financial calendar for 2020

    December 4, 2019
    Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today released its 2020 financial calendar: March 10, 2020: Publication of 2019 financial statements, with...
  • Innate Pharma certified as a Great Place to Work®

    December 3, 2019
    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) today announced its certification as a great work place by the independent institute, Great Place to Work®, a global...
  • Innate Pharma third quarter 2019 report

    November 13, 2019
    Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...
  • Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting

    November 7, 2019
    Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the...
  • Number of shares and voting rights of Innate Pharma as at November 1, 2019

    November 6, 2019
    Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...
  • Innate Pharma announces preclinical data presentations at SITC 2019

    November 6, 2019
    Preclinical data showcases advancement of its immuno-oncology portfolio across the Company’s three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  •  ›
  •  »
Updated on Thu, 12/22/2016 - 19:02

News

  • Press releases
  • Events
  • Innate in the news

Ongoing & upcoming events

All events
  • Contact
  • Location
  • Site map
  • Legal Info

Profile

  • Leadership team
  • Supervisory board
  • Strategic advisory board
  • Founders
  • History
  • Key figures
  • Key competencies

Science

  • Innate Pharma, the innate immunity company
  • Immunity & Immunotherapy
  • Bispecific antibodies
  • Bibliography

Pipeline

  • Monalizumab
  • Anti-Siglec-9

  • LUMOXITI
  • Lacutamab / IPH4102
  • IPH61
  • IPH43
  • NKp46 NKCE

  • IPH5401
  • IPH5201
  • IPH5301

Partners

Investors

News

  • Press releases
  • Events
  • Innate in the news

Career

  • GREAT PLACE TO WORK

Actus

Follow us

Stay in touch

Subscribe to our newsletter

Contact us

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

+33 (0)4 30 30 30 30

Home